A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

This 3 arm randomized open label study will evaluate the safety, tolerability and efficacy
of tocilizumab in patients with moderate to severe active rheumatoid arthritis, who have had
inadequate response to or are unable to tolerate DMARDs. Patients will be randomized to
receive tocilizumab either 4mg/kg iv or 8mg/kg iv with concomitant non-biologic DMARDs, or
8mg/kg iv without concomitant non-biologic DMARDs, every 4 weeks, for a total of 6
infusions. The anticipated time on study treatment is 3-12 months, and the target sample
size is 500-1000 individuals.